Skip to main content
SpringerLink
Log in

Experience of the treatment with Sehydrin (Hydrazine Sulfate, HS) in the advanced cancer patients

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The results of Sehydrin (Hydrazine Sulfate, HS) treatment of 740 patients with the advanced, recurrent or metastatic solid tumours of various localizations or malignant lymphomas, for whom all the methods of specific treatment (surgery, radiation, chemotherapy) had been exhausted are presented in this work. The objective response, symptomatic therapeutic effects and toxicity were estimated. Clinically significant objective responses were registered in patients with the soft tissue sarcomas, including neuroblastomas, and paradoxically—in such semimalignant tumours as desmoids. Although the objective response in patients with the lung cancer (90%—non-small cell) was only 4%, stabilization of long duration was registered in 22% of cases connected with the impressive relief of heavy common symptoms in 38.5% of the treated patients. Such a subjective response was established in 46.6% of all the 740 cases. The drug given per os was well tolerated by patients in primary and subsequent courses and did not induce myelosuppression or other significant side effects. On the basis of observations available, Sehydrin may be assessed as an alternative drug for the treatment and symptomatic therapy of patients with some advanced solid tumours and malignant lymphomas at a disease stage when the other methods of treatment can not be used. A possible mechanism of antitumour and symptomatic action is being discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gold J: Use of hydrazine sulfate in terminal and pre-terminal cancer patients: results of investigational new drug study in 84 evaluated patients Oncology 32:1–10 1975

    Article  PubMed  CAS  Google Scholar 

  2. Gold J: Hydrazine sulfate and cancer cachexia. Nutrition and Cancer I: n4, 4–9 1979.

    Google Scholar 

  3. Lerner HJ, Regelson W: Clinical trial of hydrazine sulfate in solid tumours. Cancer Treat Rep 60:959–960 1976

    PubMed  CAS  Google Scholar 

  4. Ochoa M, Wittes RE, Krakoff IH: Trial of hydrazine sulfate in patients with cancer. Cancer Chemother Rep Part I 59:1151–1154 1975

    Google Scholar 

  5. Spremulli E, Wampler GL, Regelson W: Clinical study of hydrazine sulfate in advanced cancer patients. Cancer Chemother Pharmacol 3:121–124 1979.

    Article  PubMed  CAS  Google Scholar 

  6. Strum SB, Bierman HR, Thompson R: Hydrazine sulfate in patients with neoplasia. Proc Amer Assoc Cancer Res and Amer Soc Clin Oncol 16:243 1975

    Google Scholar 

  7. Gold J: Hydrazine sulfate in the treatment of cancer. Cancer Treat Rep 60:964–965 1976

    PubMed  CAS  Google Scholar 

  8. Gold J: Method of treating cancerous cachexia in humans with hydrazine sulfate. US Patent 4:110, 437, 1978

    Google Scholar 

  9. Gold J: Anabolic profiles in late-stage cancer patients responsive in hydrazine sulfate. Nutrition and Cancer 3: n. 1, 13–19 1981

    PubMed  CAS  Google Scholar 

  10. Chlebowski RT, Bulcavage L, Grosvenor M, Tsunokai R, Block JB, Heber D, Scrooc M, Chlebowski JS, Jocelchi J, Oktay E, Akman S, Ali I: Hydrazine sulfate in cancer patients with weight loss. Cancer 59:406–410 1987

    Article  PubMed  CAS  Google Scholar 

  11. Chlebowski RT, Bulcavage L, Grosvenor M, Oktay E, Block JB, Chlebowski JS, Ali I, Elaskoff R: Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J Clin Oncol 8:9–15 1990.

    PubMed  CAS  Google Scholar 

  12. Filov VA, Stukov AN, Blank MA, Neischtadt EL Experimental data on the toxic action of hydrazine sulfate on the organism and tumour. Farmakologia i Toksikologia (Rus) 2:203–205 1978

    Google Scholar 

  13. Gershanovich ML, Danova LA, Ivin BA, Filov VA: Results of clinical study of antitumour action of hydrazine sulfate. Nutrition and Cancer 3:n. 1, 7–12 1981

    Article  PubMed  CAS  Google Scholar 

  14. Gershanovich ML, Danova LA, Kondratyev VB, Malyugina LL, Stukov AN, Seitz JF, Filov VA: Clinical data on the antitumour activity of hydrazine sulfate. Cancer Treat Rep 60:933–935 1976

    PubMed  CAS  Google Scholar 

  15. Seitz IF, Gershanovich ML, Filov VA, Danova LA, Kondratyev VB, Maljugina LL, Muller NR, Polkina VF, Rudakov VG, Stukov AN. Experimental and clinical data on antitumour action of hydrazine sulfate. Voprosy Oncologii (Rus) I:45–52 1975

    Google Scholar 

  16. Danova LA, Kondratyev VB, Gershanovich ML, Filov VA: The results of hydrazine sulfate administration in lymphogranulomatosis. Terapevticheski Arkhiv (Rus) 8:45–47 1977

    Google Scholar 

  17. Kosty MP, Fleischman SB, Herndon II JE, Coughlin K, Kornblith AB, Scalzo A, Morris JC, Mortimer J, Green MR: Cisplatin, vinblastine, and hydrazine sulfate in advanced non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the cancer and leukemia group B. J Clin Oncol 12:1113–1120 1994

    PubMed  CAS  Google Scholar 

  18. Loprinzi ChL, Goldberg RW, Su JQ, Mailliard JA, Kurross SA, Maksymiuk AW, Kugler JW, Jett JR, Ghosh C, Pfeifle DM, Wender DB, Burch PA: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 12: 1126–1129 1994

    PubMed  CAS  Google Scholar 

  19. Loprinzi ChL, Kurross SA, O’Fallon JR, Gesme DH, Gerstner JB, Rospond RM, Cobau ChD, Goldberg RM: Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 12:1121–1125 1992

    Google Scholar 

  20. Filov VA, Danova LA, Gershanovich ML, Tretjakov AV, Ivin BA. Hydrazine sulfate: experimental and clinical data, mechanisms of action. In: Drug Therapy of Tumours in Experiments and Clinic. Leningrad (Rus), 91–139, 1983

  21. Tretjakov AV, Filov VA, Ryazanov AS, Tarkov AS: Experimental data on hydrazine sulfate antitumour action. Voprosy Onkologii (Rus) 6:100–103 1979

    Google Scholar 

  22. Mashkovsky MD, Andreyeva NI, Polezhaeva AI: MAO inhibitors as a drug therapy. Khim-Pharm J (Rus) 2:6–12 1980

    Google Scholar 

  23. Baumanis EA: Search for anticarcinogenic agents among regulators of aminooxydase activity. Izvestia of the Latvian Academy of Sci (Rus) 6:72–86 1981

    Google Scholar 

  24. Veksler IG: Psychotropic drugs and their role in combined drug therapy of malignant neoplasms. Experimentalnaya Onkologia (Rus) 5:14–20 1983

    CAS  Google Scholar 

  25. Gold J: Cancer cachexia and gluconeogenesis. Ann N Y Acad Sci 30:103–110 1974

    Article  Google Scholar 

  26. Misheneva VS, Burova TM, Goryukhina TA: The influence of hydrazine sulfate on the activity of phosphoenolpyruvate-carboxykinase and the growth of experimental tumours. Voprosy Oncologii (Rus) 7:71–73 1980

    Google Scholar 

  27. Filov VA, Burova TM: Gluconeogenesis in hydrazine sulfate treatment of animals with experimental tumours. Bull of Exper Biol Med (Rus) I:73–74 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Prof. N.N. Petrov Research Institute of Oncology, 68 Leningradskaya str., Pesochny-2, 189646, St. Petersburg, Russia

    Vladimir A. Filov, Michail L. Gershanovich, Lidia A. Danova & Boris A. Ivin

Authors
  1. Vladimir A. Filov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michail L. Gershanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lidia A. Danova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Boris A. Ivin
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Phase II of Hydrazine Sulfate was carried out according to the Pharmacological Committee of the Ministry of Health of Russia request. HS is permitted for use in the medical practice for the oncological patients under the name of Sehydrin by the decision of the Pharmacological Committee of Russia taken on December, 26, 1991.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filov, V.A., Gershanovich, M.L., Danova, L.A. et al. Experience of the treatment with Sehydrin (Hydrazine Sulfate, HS) in the advanced cancer patients. Invest New Drugs 13, 89–97 (1995). https://doi.org/10.1007/BF02614227

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02614227

Key words

Search

Navigation